GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Stats] number needed to treat, or i am not interested — 13 comments in the full submission. View in context.
489
c/trialwatch·submitted 20 days ago by u/pancreatitis_scare

[Stats] number needed to treat, or i am not interested

Statsbranch of 7 comments

number needed to treat, or i am not interested, and I am aware this is a minority view on this board. Read a press release and the publication three months apart. The hedging in the second one was substantial. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact…

Read the full submission and all 13 comments →

This branch

7 comments, started 19 days ago
u/draw_up_dizzy74 points·19 days ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/hub_opssite staff-30 points·19 days ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/eu_apotheke_a1 point·19 days ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/pancreatitis_scareOP1 point·19 days ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
[deleted]1 point·19 days ago

[deleted]

replysharereportpermalink
u/hamza_zielinski1 point·19 days ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/hugo_bergstrom1 point·19 days ago

registry entry, protocol, publication — three different documents

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →